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The expression of phosphatidylserine-specific phospholipase A1 (PS-PLA1) is most upregulated in the genes
of peripheral blood cells from chronic rejection model rats bearing long-term surviving cardiac allografts.
The expression profile of PS-PLA1 in peripheral blood cells responsible for the immune response may
indicate a possible biological marker for rejection episodes. In this study, PS-PLA1 mRNA expression was
examined in human THP-1-derived macrophages. The effects of several immunosuppressive agents on this
expression were also examined in in vitro experiments. A real-time RT-PCR analysis revealed that PS-PLA1
mRNA expression was found in human THP-1-derived macrophages. This expression was enhanced in the
cells stimulated with lipopolysaccharide (LPS), a toll-like receptor (TLR) 4 ligand. Other TLR ligands
(TLR2, 3, 5, 7, and 9) did not show a significant induction of PS-PLA1 mRNA. The time course of the
mRNA expression profiles was different between PS-PLA1 and tumor necrosis factor-α (TNF-α), which
showed a maximal expression at 12 and 1 h after LPS stimulation, respectively. Among the observed immu-
nosuppressive agents, corticosteroids, prednisolone, 6α-methylprednisolone, dexamethasone, and beclometh-
asone inhibited PS-PLA1 expression with half-maximal inhibitory concentrations less than 3.0 nM, while
methotrexate, cyclosporine A, tacrolimus, 6-mercaptopurine, and mycophenoic acid showed either a weak
or moderate inhibition. These results suggest that the expression of PS-PLA1 mRNA in THP-1-derived
macrophages is activated via TLR4 and it is inhibited by corticosteroids, which are used at high dosages to
suppress chronic allograft rejection.
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INTRODUCTION PS-PLA1, an enzyme of the lipase family, acts specif-
ically on phosphatidylserine (PS) and hydrolyzes fatty
acid from the sn-1 position of PS to produce lysophos-The control of chronic rejection is important for long-
term graft survival in organ transplantation, because this phatidylserine (lysoPS) and fatty acid (6,7,16,20,24).
Because both PS and lysoPS are associated with the acti-is a significant cause of graft loss during the first year
following transplantation (11). Therefore, specific and vation of immune cells, including macrophages via PS
and lysoPS receptors (15,18,19,21), the activity of PS-sensitive markers predicting the chronic rejection are re-
quired for improving the clinical outcome. The current PLA1 might be important for the immune response in
regulating the production or elimination of PS andstudy used a high-throughput microarray analysis to
demonstrate that phosphatidylserine-specific phospholi- lysoPS (1,2). A marked elevation of the PS-PLA1 ex-
pression is observed in rats treated with lipopolysaccha-pase A1 (PS-PLA1) showed the highest upregulated ex-
pression among all the observed genes in peripheral ride (LPS) (4), thus suggesting that PS-PLA1 plays a role
in the activated immune system (1), which is associatedblood cells from chronic rejection model rats with long-
term surviving cardiac allografts (12). with chronic rejection (11). The current study focused
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on the expression profile of PS-PLA1 in immune cells polyinosine-polycytidylic acid [poly(I:C)], flagellin (from
B. subtilis), loxoribine and oligonucleotide 2006 (ODN2006)as sample specimens for clinical application.
This study examined PS-PLA1 mRNA expression in were purchased from InvivoGen (San Diego, CA) and
prepared according to the manufacturer’s instructions.human THP-1-derived macrophages stimulated by toll-
like receptor (TLR) ligands, including LPS. The effects RPMI-1640 medium, dimethyl sulfoxide (DMSO), pred-
nisolone (PSL), 6α-methylprednisolone (MPSL), 6-of immunosuppressive agents on the expression were
also examined using this in vitro system. mercaptopurine monohydrate (6MP), tacrolimus (TAC),
dexamethasone (DEX), and mycophenoic acid (MPA)MATERIALS AND METHODS
were purchased from Sigma-Aldrich (St. Louis, MO).
Materials and Reagent Solutions Beclomethasone dipropionate (BDP) was purchased
from MP Biomedicals (Solon, OH). MethotrexateLPS (ultra-pure lipopolysaccharide, from Escherichia
coli K12), heat-killed Listeria monocytogenes (HKLM), (MTX), cyclosporine A (CYA), and phorbol 12-myris-
Figure 1. Time course profile of the LPS-mediated upregulation of mRNA expression for PS-PLA1, cPLA2α, and TNF-α in THP-
1 macrophages. Differentiated THP-1 cells were incubated for 1–34 h with/without 10−5 g/ml of LPS. The relative mRNA levels
of PS-PLA1 (upper panel, left axis: with LPS, filled circles; without LPS, open circles), cPLA2α (upper panel, right axis: with LPS,
filled diamonds; without LPS, open diamonds) and TNF-α (lower panel: with LPS, filled squares; without LPS, open squares) to
GUS were determined respectively by quantitative real-time RT-PCR. The results are shown as the mean ± SD of three independent
experiments.
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Table 1. Effects of Immunosuppressive Agents CCTTCCTTAGCAGTAACATCACC-3′; antisense, 5′-
on mRNA Expression CAAACTCGGTTGGAAGACTGAA -3′), group IVA
cytosolic PLA2 (cPLA2α) (sense, 5′-ACTCCAGATCC
mRNA Expression Versus GUS CTATGTGGAAC-3′; antisense, 5′-GCTGTCCCTAGA(×10, Mean ± SD)
GTTTCATCCAT-3′), tumor necrosis factor-α (TNF-α)
(sense, 5′-ATCTACTCCCAGGTCCTCTTCAA-3′; anti-Stimuli PS-PLA1 cPLA2α
sense, 5′-GCAATGATCCCAAAGTAGACCT-3′), β-gluc-
None 0.00 (detected)* 4.86 ± 0.49 uronidase (GUS) (sense, 5′-TGATGGAAGAAGTGGT
LPS 2.08 ± 0.73 11.90 ± 2.18 GCGTAG-3′; antisense, 5′-AGTTGCTCACAAAGGT
LPS + PSL 0.09 ± 0.02† 1.68 ± 0.34† CACAGG-3′), glyceraldehyde-3-phosphate dehydroge-
LPS + MPSL 0.06 ± 0.01† 1.37 ± 0.29†
nase (GAPDH) (sense, 5′-GCCAAGGTCATCCATGALPS + DEX 0.03 ± 0.01† 0.98 ± 0.15†
CAACT-3′; antisense, 5′-GAGGGGCCATCCACAGTLPS + BDP 0.15 ± 0.10† 1.86 ± 0.27†
CTT-3′).LPS + MTX 0.97 ± 0.20† 5.04 ± 0.70†
Total RNA was extracted by Isogen (Nippon Gene,LPS + 6MP 1.51 ± 0.39 6.09 ± 2.35†
Tokyo, Japan) into TE according to the manufacturer’sLPS + CYA 1.49 ± 0.33 9.00 ± 1.21†
LPS + TAC 1.94 ± 0.53 7.67 ± 0.85† instructions. Single-strand cDNA was synthesized with
LPS + MPA 2.04 ± 0.37 9.48 ± 0.20‡ SuperScriptTM III Reverse Transcriptase and real-time
PCR was performed with a dsDNA binding dye, SYBRLPS, lipopolysaccharide; PSL, prednisolone; MPSL, 6α-methylpred-
Green I, using SuperScriptTM III Platinum Two-Stepnisolone; DEX, dexamethasone; BDP, beclomethasone dipropionate;
MTX, Methotrexate; 6MP, 6-mercaptopurine monohydrate; CYA, qPCR Kit with SYBR Green (Invitrogen, Carlsbad, CA).
cyclosporine A; TAC, tacrolimus; MPA, mycophenoic acid. Fluorescence was detected with Mx3000P system (Stra-
*Detected mean value was 0.000840.
tagene, La Jolla, CA) and analyzed with MxPro software†p < 0.01 versus LPS.
‡p < 0.05 versus LPS. (Stratagene). The expression levels of mRNA for each
gene were normalized by that of GUS.
All data are presented as the mean ± SD. Nonre-
tate 13-acetate (PMA) were purchased from Wako peated measures ANOVA followed by Dunnett’s test
Chemicals (Osaka, Japan). Fetal bovine serum (FBS) was used to assess any significant differences between
was purchased from JRH Biosciences (Lenexa, KS). All the absolute values. Significance was set at p < 0.05.
other reagents and solvents for the assay were of either
analytical or regent grade and they were purchased from RESULTSWako Chemicals or Sigma-Aldrich.
PS-PLA1 mRNA Expression in Human
THP-1-Derived MacrophagesCell Culture
The THP-1 human monocytic cell line (ATCC, TIB- The PS-PLA1 mRNA expression was compared with
the expression of TNF-α mRNA (positive control for202) was maintained in RPMI-1640 medium supple-
mented with 10% heat-inactivated FBS, 2 mM L-gluta- TLR response) in the THP-1-derived macrophages after
treating the cells with several TLR ligands for 1 andmine, 100 U/ml penicillin, 100 µg/ml streptomycin at
37°C in 5% CO2. Differentiated THP-1 cells were ob- 12 h. Among the TLR ligands [HKLM, poly(I:C), LPS,
flagellin, loxoribine, and ODN2006 for TLR2, TLR3,tained by treatment with 5 nM PMA for 2 days and then
were starved overnight in RPMI-1640 medium containing TLR4, TLR5, TLR7, and TLR9, respectively], LPS in-
duced PS-PLA1 expression at 12 h after treatment, while0.5% FBS and 5 nM PMA. They were thereafter stimu-
lated with 0–10−5 g/ml LPS in the presence of 10% heat- no other ligands exhibited such induction (data not
shown). On the other hand, TNF-α mRNA was inducedinactivated FBS for up to 34 h. In some experiments, dif-
ferentiated THP-1 cells were stimulated with HKLM (108 when the cells were treated with HKLM, LPS, and fla-
gellin for 1 h (data not shown).cells/ml), poly(I:C) (25 mg/ml), flagellin (10−5 g/ml), lox-
oribine (1 mM), or ODN2006 (5 mM) instead of LPS. To LPS treatment increased PS-PLA1 mRNA expression
on THP-1-derived macrophages 800-fold, which wasinvestigate the effects of immunosuppressants, cells were
treated with 10−5 M of PSL, MPSL, DEX, BDP, MTX, four times greater than that of cPLA2α (Fig. 1). The
upregulation of PS-PLA1 mRNA was LPS dose depen-6MP, CYA, or TAC together with/without LPS (10−5 g/
ml) for 12 h. Dose dependency was also examined in dent at the concentration of 10−9–10−5 g/ml (data not
shown). The time course profiles of mRNA expression10−9–10−4 M of PSL, MPSL, DEX, and BDP.
after LPS stimulation was different between PS-PLA1Quantitative Real-Time RT-PCR Analysis and TNF-α. The maximum mRNA expression for PS-
PLA1 and TNF-α was at 12 and 1 h after LPS stimula-Primer sets used were synthesized at Invitrogen (Carls-
bad, CA). The primer sets were: PS-PLA1 (sense, 5′- tion, respectively (Fig. 1).
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Figure 2. Dose-dependent inhibition of the mRNA expression for PS-PLA1 and cPLA2α by corti-
costeroids. Differentiated THP-1 cells were incubated for 12 h at different concentrations of PSL
(open bars), MPSL (dotted bars), DEX (shaded bars), or BDP (hatched bars) in the presence of 10−5
g/ml of LPS. The relative mRNA levels of PS-PLA1 (a) and cPLA2α (b) to GUS were determined,
respectively, by quantitative real-time RT-PCR. The results are shown as the mean ± SD of three
independent experiments.
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Effects of Immunosuppressive Agents on PS-PLA1 nitude of the inhibitory effects for PS-PLA1 mRNA
expression was almost the same as those for cPLA2αmRNA Expression
(Fig. 2). This means that corticosteroids may exert dif-Among the immunosuppressive agents, corticoste-
ferent immunosuppressive effects on the status of PS-roids (PSL, MPSL, DEX, and BDP) showed marked in-
PLA1 expression via TLR4 activation. High-dose corti-hibition of PS-PLA1 mRNA expression, while other
costeroids for chronic rejection (8) may therefore be aagents, MTX, CYA, TAC, 6MP and MPA, showed
reasonable therapeutic strategy if PS-PLA1 plays an im-weak or little effects (Table 1). The inhibitory effects of
portant role. Further study is thus required to confirmcorticosteroids on PS-PLA1 mRNA expression were
this speculation.dose dependent (Fig. 2). The half-maximal inhibitory
In conclusion, PS-PLA1 mRNA was specifically ex-concentration (IC50) for PSL was 3.0 nM (Fig. 2). The
pressed via TLR4 activation in THP-1-derived macro-inhibitory effects of corticosteroids on mRNA expres-
phages. This expression was inhibited by corticoste-sion for cPLA2α were similar to those for PS-PLA1 (Fig.
roids, but not by other immunosuppressive agents. The2). Other agents inhibited cPLA2α mRNA expression,
clinical application of this potential treatment modalityalthough the inhibitory effects were weaker than that for
in allograft immunity therefore requires further investi-corticosteroids (Table 1).
gation.
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